Core Viewpoint - The article highlights the successful IPO of Nanjing Weili Zhizhi Biotechnology Co., Ltd. on the Hong Kong Stock Exchange, emphasizing the long-term investment strategy and support from Huafang Capital throughout the company's development journey [1][3]. Group 1: Company Overview - Nanjing Weili Zhizhi Biotechnology, founded in 2012, focuses on discovering, developing, and commercializing new therapies for tumors, autoimmune diseases, and other major diseases [3]. - The company became the first stock in the TCE (T-cell Engager) field in China, backed by top-tier institutions including Morgan Stanley and CITIC Securities, with cornerstone subscriptions exceeding half of the total issuance [3]. Group 2: Investment Journey - Huafang Capital's initial investment in Weili Zhizhi in 2018 marked a significant turning point, as the company was still in the pre-clinical stage at that time [4]. - In 2019, Huafang Capital, along with its parent company, led a new round of investment totaling 200 million yuan to help Weili Zhizhi navigate through a critical phase of development [5]. Group 3: Market Performance - On its first day of trading on July 25, 2025, Weili Zhizhi's stock opened at 72.4 HKD per share, reaching a peak of 79.6 HKD, with a maximum increase of 127.43%, and closing at 67.1 HKD, reflecting a 91.71% rise, resulting in a market capitalization of 12.97 billion HKD [1][3]. Group 4: Huafang Capital's Strategy - Established in 2017, Huafang Capital specializes in early-stage investments in high-end manufacturing, biomedicine, and new-generation information technology, leveraging its extensive industry and capital operation experience [6]. - The firm emphasizes post-investment empowerment and has formed a strategic layout targeting leading companies in niche sectors [6].

Core Viewpoint - Nanjing Weilizhibo Biotechnology Co., Ltd. is set to become the first domestic TCE (T-cell engager) company to go public, with an IPO market value estimated between HKD 59.58 billion and HKD 65.99 billion [2][3]. Group 1: IPO Details - The IPO will involve the issuance of 32,054,400 H-shares, with 3,205,500 shares available for public offering in Hong Kong and 28,848,900 shares for international offering [2]. - The share price is set between HKD 31.60 and HKD 35.00, leading to the aforementioned market value range [2]. - The company has secured 9 cornerstone investors who have collectively subscribed for USD 69 million (approximately HKD 541.6 million) [2]. Group 2: Company Overview - Founded in 2012, Weilizhibo focuses on discovering, developing, and commercializing new therapies for cancer, autoimmune diseases, and other major diseases [2]. - The company currently has one core product, LBL-024, which is undergoing evaluation for its efficacy in treating various types of cancer, including advanced pulmonary neuroendocrine carcinoma and small cell lung cancer [3]. Group 3: Product Pipeline - LBL-024 is the first 4-1BB targeted candidate drug to reach the registration clinical trial stage globally for advanced pulmonary neuroendocrine carcinoma [3]. - The company has 13 other candidate drugs in its pipeline, including 5 in clinical stages and 8 in preclinical stages [3]. - Notable products include LBL-034, a leading GPRC5D-targeted CD3 T-cell engager, and LBL-033, one of the two MUC16/CD3 bispecific antibodies in clinical stages [3]. Group 4: Use of Proceeds - Approximately 65% of the net proceeds from the IPO will be allocated to clinical development and regulatory affairs for ongoing and planned clinical candidates [4]. - About 15% will be used to advance preclinical assets and optimize the technology platform [4]. - The remaining funds will be directed towards enhancing production capacity, commercialization post-approval, and general corporate purposes [4].